Cowen analyst, Ritu Baral, reiterated her Outperform rating on shares of Acadia Pharmaceuticals (NASDAQ: ACAD) and raised her price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE